Hemostasis and Related Disorders

Introduction to Hemostasis

Hemostasis is the physiological process that stops bleeding at the site of an injury while maintaining normal blood flow elsewhere in the circulation. It involves a complex interplay between blood vessels, platelets, and coagulation factors, and is tightly regulated by numerous activators and inhibitors.

• Definition: Hemostasis is the "stopping of blood flow" to prevent excessive bleeding following vascular injury.

• Phases: The process consists of four main phases: vasoconstriction, formation of a platelet plug, coagulation (fibrin clot formation), and clot retraction/dissolution.

• Clinical Relevance: Disorders of hemostasis can lead to either excessive bleeding or unwanted clotting (thrombosis).

Phases of Hemostasis

Vasoconstriction

Vasoconstriction is the immediate narrowing of a blood vessel following injury, reducing blood loss and facilitating the next steps of hemostasis.

• Mechanism: Local contraction of vascular smooth muscle, mediated by factors released from platelets and damaged endothelium.

• Mediators: Thromboxane A2 (TXA2) from platelets, endothelin-1, and catecholamines (epinephrine/norepinephrine).

• Purpose: Reduces local blood flow and limits blood loss.

Platelet Plug Formation

Platelet plug formation is a rapid response to vascular injury, involving platelet adhesion, activation, and aggregation at the site of damage.

• Platelet Adhesion: Platelets adhere to exposed subendothelial collagen via von Willebrand Factor (vWF), which acts as a bridge between platelets and the vessel wall.

• Platelet Activation: Adhered platelets become activated, releasing ADP and other mediators that attract additional platelets.

• Platelet Aggregation: Platelets bind to each other via glycoprotein receptors, forming a temporary "platelet plug" to seal small vessel injuries.

Coagulation (Fibrin Clot Formation)

The coagulation cascade stabilizes the platelet plug by forming a meshwork of fibrin, resulting in a stable blood clot.

• Inactive Proteins: Coagulation factors circulate in an inactive form and are sequentially activated in a cascade.

• Pathways: There are two main pathways—intrinsic and extrinsic—which converge on a common pathway leading to fibrin formation.

• Fibrin Mesh: Fibrin strands interlace with platelets to stabilize the clot.

Key Equation:

Clot Retraction and Dissolution

After the clot is formed, it undergoes retraction and eventual dissolution to restore normal blood flow and tissue integrity.

• Clot Retraction: Platelets contract, pulling the edges of the damaged vessel together and expelling serum from the clot (occurs within 30 minutes).

• Clot Dissolution (Fibrinolysis): Plasminogen is converted to plasmin, which digests fibrin and dissolves the clot. Protein C and S deactivate certain coagulation factors to regulate the process.

Hemostasis Disorders

Classification of Hemostatic Disorders

Hemostatic disorders are broadly classified based on whether they primarily affect platelets or coagulation factors, and whether they result in excessive bleeding or clotting.

• Platelet-Related Disorders: Affect platelet number or function.

• Coagulation-Related Disorders: Affect the coagulation cascade.

• Clinical Manifestations: Disorders may increase the risk of bleeding or thrombosis (clotting).

Clotting (Thrombotic) Disorders

Platelet-Related Clotting Disorders

• Increased Platelet Function: Conditions such as hypertension, diabetes, and atherosclerosis can activate platelets and promote arterial thrombosis (common in high-flow arteries).

• Increased Platelet Quantity (Thrombocytosis): Seen in polycythemia vera, cancer, and chronic inflammatory diseases.

Coagulation-Related Clotting Disorders

• Genetic Mutations: Factor V Leiden mutation (resistance to inactivation by Protein C), prothrombin gene mutation (increased prothrombin), deficiencies of Protein C, S, or antithrombin.

• Acquired Conditions: Prolonged immobility, vessel wall damage, hypercoagulable states (e.g., antiphospholipid syndrome).

• Venous Thrombosis: More common in veins due to stasis and hypercoagulability.

Bleeding Disorders

Platelet-Related Bleeding Disorders

• Thrombocytopenia (Low Platelet Count): Due to decreased production (bone marrow failure), increased destruction (immune-mediated, hypersplenism), or drug-induced causes.

• Platelet Dysfunction: Can be inherited (e.g., Glanzmann thrombasthenia), acquired (uremia due to renal failure), or drug-induced (antiplatelet agents such as aspirin).

• von Willebrand Disease: Affects both platelet function and coagulation (see below).

Coagulation-Related Bleeding Disorders

• Inherited Deficiencies: Hemophilia A (Factor VIII deficiency), Hemophilia B (Factor IX deficiency), von Willebrand disease (vWF deficiency).

• Acquired Deficiencies: Liver disease, vitamin K deficiency, disseminated intravascular coagulation (DIC).

Disseminated Intravascular Coagulation (DIC)

DIC is a complex disorder characterized by widespread activation of the coagulation system, leading to both thrombosis and bleeding.

• Pathophysiology: Microthrombi form in small vessels, causing tissue ischemia. Coagulation factors and platelets are rapidly consumed, leading to bleeding as they are depleted faster than they can be produced.

• Common Causes: Trauma, severe infections, malignancy.

Laboratory Assessment of Hemostasis

Laboratory tests are essential for diagnosing and monitoring hemostatic disorders.

Treatment Overview

Coagulation Disorders

• Fresh Frozen Plasma (FFP): Contains all coagulation factors; used for multiple factor deficiencies.

• Cryoprecipitate: Rich in fibrinogen, von Willebrand factor, and Factor VIII; used for specific deficiencies.

• Prothrombin Complex Concentrate (PCC): Contains Factors II, VII, IX, X; used for rapid reversal of anticoagulation.

Bleeding Disorders

• Platelet Transfusion: For severe thrombocytopenia or platelet dysfunction.

• Desmopressin (DDAVP): Stimulates release of vWF and Factor VIII (useful in mild hemophilia A and von Willebrand disease).

• Antifibrinolytic Agents: Such as tranexamic acid, to prevent clot breakdown.

Summary Table: Platelet vs. Coagulation Disorders

Additional info: Some details, such as normal laboratory values and specific examples of disorders, were inferred from standard academic sources to provide a complete and self-contained study guide.